Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Smith, David Hersi ^a,b   Fiehn, Anne Marie Kanstrup ^c   Fogh, Louise ^b   Christensen, Ib Jarle ^d   Hansen, Tine Plato ^e   Stenvang, Jan ^b   Nielsen, Hans Jørgen ^b   Nielsen, Kirsten Vang ^a,f   Hasselby, Jane Preuss ^c   Brünner, Nils ^b   Jensen, Sussie Steen ^a  

^a AGILENT TECHNOLOGIES   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f Research and Innovation Centre   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY SPECIFICITY; CANCER STAGING; COHORT ANALYSIS; DIAGNOSTIC USE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; NEOPLASMS; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; COHORT STUDIES; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS;

EID: 84896798481     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04313     Document Type: Article

References (37)

1. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C. & Parken, D. M. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. (2010) (Date of access: 31/7/2013).
2. Colucci, G. et al. Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23, 4866-4875 (2005).
3. Woynarowski, J. M. et al. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol. 58, 920-927 (2000).
4. Rabik, C. A. & Dolan, M. E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9-23 (2007).
5. Martin, L. P., Hamilton, T. C. & Schilder, R. J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 14, 1291-1295 (2008).
6. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 11, 467-480 (2011).
7. Bhagwat, N. et al. XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair. Mol. Cell. Biol. 29, 6427-6437 (2009).
8. Niedernhofer, L. J. et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol. Cell Biol. 24, 5776-5787 (2004).
9. Olaussen, K. A. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991 (2006).
10. Shirota, Y. et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19, 4298-4304 (2001).
11. Braun, M. S. et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26, 2690-2698 (2008).
12. Koopman, M. et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer. 45, 1999-2006 (2009).
13. Kim, S. H. et al. Prognostic Value of ERCC1, Thymidylate Synthase, and Glutathione S-Transferase [pi] for 5-FU/Oxaliplatin Chemotherapy in Advanced Colorectal Cancer. Am. J. Clin. Oncol. 32, (2009).
14. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J.& Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin. Invest. 94, 703-708 (1994).
15. Booton, R. et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac. Oncol. 2, 902-906 (2007).
16. Metzger, R. et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin. Oncol. 16, 309-316 (1998).
17. Bhagwat, N. R. et al. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 69, 6831-6838 (2009).
18. Ma, D. et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC biotechnology. 12, 88 (2012).
19. Friboulet, L. et al. ERCC1 Isoform Expression and DNA Repair in Non2Small- Cell Lung Cancer. N. Engl. J. Med. 368, 1101-1110 (2013).
20. Yagi, T., Tatsumi-Miyajima, J., Sato, M., Kraemer, K. H. & Takebe, H. Analysis of Point Mutations in an Ultraviolet-irradiated Shuttle Vector Plasmid Propagated in Cells from Japanese Xeroderma Pigmentosum Patients in Complementation Groups A and F. Cancer Res. 51, 3177-3182 (1991).
21. Hansen, T. P. Immunohistochemical Tumor Markers in Colorectal Cancer: A Methodological and Prognostic Study. (University of Southern Denmark, Odense, 2002).
22. Kjeldsen, B. J., Kronborg, O., Fenger, C. & J?gensen, O. D. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg. 84, 666-669 (1997).
23. Smith, D. H. et al. Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort. PLoS. One. 8, e60613 (2013).
24. Romer, M. U. et al. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand. J. of Gastroenterol. 47, 68-79 (2012).
25. Romer, M. U. et al. Topoisomerase 1 (,i. TOP1,/i.) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol. Onc. 7, 101-111 (2012).
26. Nielsen, H. J., Christensen, I. J., Moesgaard, F. & Kehlet, H. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg. 89, 1416-1422 (2002).
27. Olaussen, K. A. & Soria, J. C. Validation of ERCC1-XPF Immunodetection 22 Letter. Cancer Res. 70, 3851-3852 (2010).
28. De,D. S. et al. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother. Pharmacol. 72, 159-165 (2013).
29. Lee, S. H. et al. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer. 81, 102-108 (2013).
30. Ting, S. et al. ERCC1, MLH1, MSH2, MSH6, and Beta-III-Tubulin: Resistance Proteins Associated With Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural Mesothelioma. Clin. Lung Cancer. (2013).
31. Reed, E. ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res. 11, 6100-6102 (2005).
32. Gaillard, P. H. &Wood, R. D. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nuc. Acids Res. 29, 872-879 (2001).
33. Matsumura, Y.,Nishigori, C., Yagi, T., Imamura, S.&Takebe, H. Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms. Hum. Mol. Genet. 7, 969-974 (1998).
34. Sijbers, A. M. et al. Mutational analysis of the human nucleotide excision repair gene ERCC1. Nuc. Acids Res. 24, 3370-3380 (1996).
35. Dapson, R. W. Macromolecular changes caused by formalin fixation and antigen retrieval. Biotech. Histochem. 82, 133-140 (2007).
36. Selfridge, J., Song, L., Brownstein, D. G. & Melton, D. W. Mice with DNA repair gene Ercc1 deficiency in a neural crest lineage are a model for late-onset Hirschsprung disease. DNA Rep. 9, 653-660 (2010).
37. Smith, D. H. et al. An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort. BMC cancer. 13, 489 (2013).